What is the latest market price of capicetinib/capasitinib in 2025?

Capivasertib, as an innovative AKT inhibitor, has been officially launched in China. Its main application direction is focused on HR+, HER2-negative breast cancer patients, especially those who have progressed after endocrine therapy and CDK4/6 inhibitor treatment. In this context, capicistat combined with fulvestrant is considered to be able to significantly improve the disease control rate and has been gradually adopted by international oncology guidelines. This makes it one of the most talked-about new breast cancer drugs in recent years, and has also triggered widespread market discussions about its price and accessibility.

From an application perspective, carpisetin is not limited to breast cancer. Early studies have shown that it has certain anti-tumor activity in a variety of tumors, laying the foundation for future market expansion. As the research on combination therapy deepens, it may be used in conjunction with immune checkpoint inhibitors, PARP inhibitors and other drugs to further improve the efficacy.

In terms of price, since Tuenkode has just been launched in China, domestic pricing and medical insurance reimbursement have not yet been made public. According to overseas market data, the original drug of carpiseti has been launched in Europe, the United States, Switzerland and other places. The common specification is 200mg*64 tablets, and the price is about more than 60,000 yuan. This level is a heavy burden for patients undergoing long-term treatment. In Laos and other places, there are imitation versions produced by pharmaceutical companies with the same specifications. The price per box is about 3,000 yuan, and the ingredients of the two are basically the same. Although the use of overseas generic drugs has obvious price advantages, the safety and compliance in the formal medical system still need to be treated with caution.

In the future, the market structure of carpiseti in China will depend on the progress of medical insurance negotiations and whether quality-controllable generic drugs will appear in the country. Once included in the medical insurance list, prices are expected to drop significantly, thereby improving patient accessibility. At the same time, with the expansion of clinical indications, its market size and application scope will be further expanded.

Reference materials:https://www.drugs.com/mtm/capivasertib.html